Skip to main content

Advertisement

Peer Review reports

From: The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review

Original Submission
21 Jan 2019 Submitted Original manuscript
16 Mar 2019 Reviewed Reviewer Report - Andrew Glory Mtewa
24 Mar 2019 Reviewed Reviewer Report - Vincenzo L'imperio
14 May 2019 Author responded Author comments - Miriam Van den Nest
Resubmission - Version 2
14 May 2019 Submitted Manuscript version 2
7 Jun 2019 Reviewed Reviewer Report - Andrew Glory Mtewa
7 Jun 2019 Reviewed Reviewer Report - Vincenzo L'imperio
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
14 Nov 2019 Editorially accepted
11 Dec 2019 Article published 10.1186/s13643-019-1235-x

You can find further information about peer review here.

Back to article page